UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000005649
Receipt number R000006676
Scientific Title The evaluation of prophylactic effect of intralesional steroid injection to prevent esophageal stricture after ESD(endoscopic submucosal dissection) of superficial esophageal cancers
Date of disclosure of the study information 2011/05/27
Last modified on 2016/12/09 10:51:19

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

The evaluation of prophylactic effect of intralesional steroid injection to prevent esophageal stricture after ESD(endoscopic submucosal dissection) of superficial esophageal cancers

Acronym

The evaluation of prophylactic effect of intralesional steroid injection to prevent esophageal stricture after ESD(endoscopic submucosal dissection) of superficial esophageal cancers

Scientific Title

The evaluation of prophylactic effect of intralesional steroid injection to prevent esophageal stricture after ESD(endoscopic submucosal dissection) of superficial esophageal cancers

Scientific Title:Acronym

The evaluation of prophylactic effect of intralesional steroid injection to prevent esophageal stricture after ESD(endoscopic submucosal dissection) of superficial esophageal cancers

Region

Japan


Condition

Condition

superficial esophageal cancers

Classification by specialty

Gastroenterology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To investigate the prophylactic effect of intralesional steroid injection to prevent esophageal stricture after ESD of superficial esophageal cancers

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1

Confirmatory

Trial characteristics_2

Explanatory

Developmental phase

Phase II


Assessment

Primary outcomes

To compare the treatment duration between 2 groups (the weekly group receive 40mg of triamcinolone acetonide weekly, the biweekly group receive 40mg of triamcinolone acetonide biweekly )

Key secondary outcomes

Frequency of EBD(endoscopic balloon dilations), Stricture rate, Frequency of adverse events


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Dose comparison

Stratification

NO

Dynamic allocation

NO

Institution consideration

Institution is not considered as adjustment factor.

Blocking

NO

Concealment

Numbered container method


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

The weekly group receive 40mg of triamcinolone acetonide weekly

Interventions/Control_2

The biweekly group receive 40mg of triamcinolone acetonide biweekly

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Relative adaptational lesion for ESD and more than 3/4 luminal circumferencial mucosal defect

Key exclusion criteria

1)Not acceptance to participate in the study
2)Allergy for triamcinolone acetonide
3)Severe DM or adrenal malfunction
4)Inappropriate for this trial

Target sample size

30


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Morita Yoshinori

Organization

Kobe University, School fo Medicine

Division name

Department of Gastroenterology

Zip code


Address

7-5-1,kusunoki-cho,cho-ku,Kobe 650-0017 Japan.

TEL

0783826305

Email

ymorita@med.kobe-u.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Morita Yoshinori

Organization

Kobe University, School fo Medicine

Division name

Department of Gastroenterology

Zip code


Address

7-5-1,kusunoki-cho,cho-ku,Kobe 650-0017 Japan.

TEL

0783826305

Homepage URL


Email

ymorita@med.kobe-u.ac.jp


Sponsor or person

Institute

Kobe University, School fo Medicine

Institute

Department

Personal name



Funding Source

Organization

Kobe University, School fo Medicine

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2011 Year 05 Month 27 Day


Related information

URL releasing protocol


Publication of results

Published


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2010 Year 08 Month 30 Day

Date of IRB


Anticipated trial start date

2010 Year 09 Month 16 Day

Last follow-up date

2012 Year 01 Month 16 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2011 Year 05 Month 26 Day

Last modified on

2016 Year 12 Month 09 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000006676


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name